NEW YORK (GenomeWeb News) – Eurofins MWG Operon today announced it has acquired gene synthesis firm Entelechon for an undisclosed amount.
Entelechon was founded in 1999 in Regensburg, Germany, and focuses on genomics and proteomics projects "bringing broad experience in the fields of gene optimization and synthesis," Eurofins MWG Operon, the genomics division of Eurofins Scientific, said. The company serves the drug manufacturing industry as well as academic and public research institutes.
Entelochon began being integrated into Eurofins MWG Operon's gene synthesis business on June 1.
"The acquisition through Eurofins should generate considerable synergies and additional value to our customers," Markus Fischer, managing director of Entelechon, said in a statement. In addition to helping in the integration process, he will remain CEO of Entelechon spinout PolyQuant, a protein expression and quantitative proteomics firm.
Bruno Poddevin, vice president of Eurofins MWG Operon, added, "Entelechon is an excellent strategic fit with Eurofins MWG Operon's genomic service offering and their competence on gene synthesis services and synthetic biology complements our DNA synthesis and sequencing units in an excellent way, while providing us with additional tools to serve the fast growing applied genetics markets. The acquisition of Entelechon is a next step to further grow the business and strengthen our position as one of the market leaders in genomic services."